Approval of Audited Financial Results for the quarter and FY ended 31-03-2026 alongwith auditors report.
NEOGEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Neogen Chemicals reported FY2026 standalone revenue of Rs 855.49 crore, up 10.6% from Rs 773.65 crore in FY2025. However, profit after tax declined 3% to Rs 46.96 crore from Rs 48.41 crore, with EPS at Rs 17.81 vs Rs 18.35. Operating cashflow turned sharply negative at Rs -99.20 crore for FY26, a major deterioration from Rs 198.76 crore positive in FY25, driven by large increases in inventories (up Rs 245 crore) and trade receivables. The board recommended a final dividend of Re 1 per share. The statutory auditor issued an unmodified (clean) opinion. The Dahej subsidiary project timeline has been delayed to Feb-Mar 2027 with revised cost of Rs 1,795 crore due to technology changeover and higher localisation capex.
Positive revenue growth was offset by PAT decline and a critical negative operating cashflow of Rs 99.20 crore, indicating working capital stress. Investors will watch the cashflow trajectory and Dahej project execution closely, as rising debt and project delays could weigh on near-term sentiment despite the clean audit opinion.